research Hedgehog Pathway Inhibitors against Tumor Microenvironment
Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch Androgen receptor inhibits the hair follicle induction potential of dermal papilla cells by binding with Tcf4 at the A574 binding site
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research - Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.
research ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.
research Plerixafor Biases CXCR4 Signaling Through β-Arrestin to Promote Melanogenesis via β-Catenin–MITF Activation
Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
research Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
research A clinical case of familial alopecia areata in combination with immune pathology
Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Drugs targeting epithelial–mesenchymal transition molecules for treatment of lichen planopilaris
Drugs targeting EMT molecules show promise for treating lichen planopilaris.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
Baricitinib is a promising treatment for alopecia areata.
research Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research CD44/TRPV1 dual-targeted nanocarrier enables drug retention and multidimensional therapy for inflammatory skin diseases
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.